RE:RE:RE:RE:RE:RE:RE:ONCY's pelareorep can provide a fine T-cell boost for ADCsImmuoGen's only approval occurred in November 2022, for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinumresistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. ImmunoGen's other solid cancer candidates are either pre-clinical or in Phase 1 stages.
Consequently, ONCY's near term registration of pelareorep in 2 early disease indications with another two in Phase 2 trials, the comparison with ImmunoGen's US$10.1 Billion acquisition is appropriate, under the circumstances now with biologics on the rise.
https://www.immunogen.com/wp-content/uploads/2022/11/ELAHERE_PI.pdf